Abstract: A method of making a multicomponent photocatalyst, includes inducing precipitation from a pre-cursor solution comprising a pre-cursor of a plasmonic material and a pre-cursor of a reactive component to form co-precipitated particles; collecting the co-precipitated particles; and annealing the co-precipitated particles to form the multicomponent photocatalyst comprising a reactive component optically, thermally, or electronically coupled to a plasmonic material.

Abstract: Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies.

Abstract: Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: A circuit for a multi-phase power regulator including a power stage with a first phase and a second phase, the circuit including phase management circuitry coupled to the first phase and the second phase to control the first phase and the second phase, a first comparator coupled to an output of the multi-phase power regulator to compare a value of the output of the multi-phase power regulator to a first threshold value to produce a first comparison result, and phase shedding circuitry coupled to the first comparator and the phase management circuitry to control the phase management circuitry to activate or deactivate the second phase based at least partially on the first comparison result.

Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.